Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
06990
Company Profile
Business description
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world’s prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Contact
No. 666 Xinhua Avenue
Chengdu Cross-Strait Science and Technology Industry Development Park
Wenjiang
Sichuan
Chengdu
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,870
Stocks News & Analysis
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,115.70 | 13.70 | -0.15% |
| CAC 40 | 7,674.78 | 24.14 | -0.31% |
| DAX 40 | 23,596.98 | 173.35 | -0.73% |
| Dow JONES (US) | 45,400.86 | 220.43 | -0.48% |
| FTSE 100 | 9,208.21 | 8.66 | -0.09% |
| HKSE | 25,508.17 | 90.19 | 0.35% |
| NASDAQ | 21,700.39 | 7.30 | -0.03% |
| Nikkei 225 | 43,555.43 | 536.68 | 1.25% |
| NZX 50 Index | 13,263.18 | 39.65 | 0.30% |
| S&P 500 | 6,481.50 | 20.58 | -0.32% |
| S&P/ASX 200 | 8,839.80 | 15.40 | -0.17% |
| SSE Composite Index | 3,818.82 | 6.31 | 0.17% |